Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
6 studies found for:    ((pazopanib AND GIST)OR Nct01391611 OR Nct01392352 OR NCT01339871 OR NCT01485042) | Open Studies
Show Display Options
RSS Create an RSS feed from your search for:
((pazopanib AND GIST)OR Nct01391611 OR Nct01392352 OR NCT01339871 OR NCT01485042) | Open Studies
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Pazopanib
2 Recruiting HYPAZ: Hypertension Induced by Pazopanib
Conditions: Renal Cell Carcinoma;   Soft Tissue Sarcoma;   Glioblastoma;   Ovarian Cancer;   Cervical Cancer;   Breast Cancer;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Pancreatic Cancer;   Melanoma;   Gastrointestinal Cancer
Intervention: Drug: Pazopanib
3 Recruiting Phase I Study of Pazopanib and Vorinostat
Condition: Advanced Cancer
Interventions: Drug: Pazopanib;   Drug: Vorinostat
4 Recruiting Caphosol in Oral Mucositis Due to Targeted Therapy
Conditions: Oral Mucositis;   Renal Cell Carcinoma;   Hepatocellular Carcinoma;   Gastrointestinal Stromal Tumors
Interventions: Other: supersaturated calcium-phosphate rinse;   Other: sodium chloride 0.9 %
5 Recruiting A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma
Condition: Soft Tissue Sarcoma
Interventions: Drug: Pazopanib;   Drug: Doxorubicin
6 Recruiting A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas
Conditions: Liposarcoma;   Osteogenic Sarcoma;   Ewing/Ewing-like Sarcoma
Interventions: Drug: Regorafenib;   Drug: Placebo

Indicates status has not been verified in more than two years